A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
NCT05471856
Recruiting
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time. Participants get B... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California +12 locations
Conditions: Solid Tumors
Register for Updates
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
Recruiting
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469
Recruiting
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS), lower risk chronic mye... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/30/2025
Locations: Stanford Cancer Center, Stanford, California +21 locations
Conditions: Myeloid Diseases
Register for Updates
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363
Recruiting
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: UC Irvine Health, Orange, California +10 locations
Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643
Recruiting
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Hoag Memorial Hospital, Newport Beach, California +15 locations
Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Register for Updates
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
NCT05663710
Recruiting
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer, Clear Cell Renal Cell Carcinoma
Register for Updates
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351
Recruiting
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: LA Universal Research Center, Inc., Los Angeles, California +261 locations
Conditions: Severe Hypertriglyceridemia
Register for Updates
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
NCT05787574
Recruiting
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells. "Fun... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2025
Locations: University of California, San Francisco (Data collection only), San Francisco, California +11 locations
Conditions: Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
Register for Updates
ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Survivors of Childhood Cancer
NCT05792566
Recruiting
Development and Usability Testing of the ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Children, Adolescent and Young Adults (AYA) survivors of childhood cancer
Gender:
ALL
Ages:
Between 10 years and 30 years
Trial Updated:
07/30/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Pediatric Cancer
Register for Updates
Risk Stratification in Children With Concussion
NCT05825027
Recruiting
This project will measure concussion symptoms, biological markers, and academic and social factors across the first year postconcussion to develop a model that enables early identification of and symptom management for children at higher risk for persistent postconcussive symptoms. Findings will provide novel insights into the longer-term effects of concussion on children's physical, psychological, and social well-being and support the development of personalized healthcare and school-based plan... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
07/30/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: Concussion, Brain, Mild Traumatic Brain Injury
Register for Updates
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
NCT05831579
Recruiting
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provide limited durability of response, and there are challenges with delivery to large tumors or in previously irradiated fields. In this study, Proton GRID radiotherapy will be used to deliver three-frac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Unresectable Solid Tumor, Metastatic Cancer
Register for Updates
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
NCT05846282
Recruiting
Students in marginalized communities who 'strive' to rise above adversity to achieve academic success are considered 'resilient'. However, youths' resilience in one domain (i.e. academic) can come at a cost in other domains including physical and mental health morbidities that are under-identified and under-treated. Previous research suggests that Black, Indigenous and People of Color (BIPOC) who exhibit a "striving persistent behavioral style" in the face of adversity evince later health morbid... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
07/30/2025
Locations: University of California, Los Angeles, California
Conditions: Internalizing Mental Health Symptoms, Allostatic Load, Health Complaints
Register for Updates